March 18, 2024 03:52 PM EDTUpdated 06:57 PM
Pharma
FDA+

Up­dat­ed: FDA ex­pands la­bel for nasal spray to treat chron­ic si­nus in­flam­ma­tion

Zachary Brennan

Senior Editor

The FDA on Fri­day signed off on a new in­di­ca­tion for Opti­nose’s nasal spray Xhance as a treat­ment for chron­ic rhi­nos­i­nusi­tis with­out nasal polyps in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times